Literature DB >> 16962592

Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells.

Beobyi Lee1, Cheorl-Ho Kim, Sung-Kwon Moon.   

Abstract

Honokiol, an active component in extracts of Magnolia officinalis, has been proposed to play a role in anti-inflammatory, antioxidant activity, anti-angiogenic and anti-tumor activity. Although honokiol has a variety of pharmacological effects on certain cell types, its effects on vascular smooth muscle cells (VSMC) are unclear. This issue was investigated in the present study, honokiol was found to inhibit cell viability and DNA synthesis in cultured VSMC. These inhibitory effects were associated with G1 cell cycle arrest. Treatment with honokiol blocks the cell cycle in the G1 phase, down-regulates the expression of cyclins and CDKs and up-regulates the expression of p21WAF1, a CDK inhibitor. While honokiol did not up-regulate p27, it caused an increase in the promoter activity of the p21WAF1 gene. Immunoblot and deletion analysis of the p21WAF1 promoter showed that honokiol induced the expression of p21WAF1 and that this expression was independent of the p53 pathway. Furthermore, the honokiol-mediated signaling pathway involved in VSMC growth inhibition was examined. Among the relevant pathways, honokiol induced a marked activation of p38 MAP kinase and JNK. The expression of dominant negative p38 MAP kinase and SB203580, a p38 MAP kinase specific inhibitor, blocked the expression of honokiol-dependent p38 MAP kinase and p21WAF1. Consistently, blockade of p38 MAPK kinase function reversed honokiol-induced VSMC proliferation and cell cycle proteins. These data demonstrate that the p38 MAP kinase pathway participates in p21WAF1 induction, subsequently leading to a decrease in the levels of cyclin D1/CDK4 and cyclin E/CDK2 complexes and honokiol-dependent VSMC growth inhibition. In conclusion, these findings concerning the molecular mechanisms of honokiol in VSMC provides a theoretical basis for clinical approaches to the use therapeutic agents in treating atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16962592     DOI: 10.1016/j.febslet.2006.08.064

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  21 in total

1.  In vitro growth inhibition of human cancer cells by novel honokiol analogs.

Authors:  Jyh Ming Lin; A S Prakasha Gowda; Arun K Sharma; Shantu Amin
Journal:  Bioorg Med Chem       Date:  2012-04-03       Impact factor: 3.641

2.  Epigenetic histone acetylation modifiers in vascular remodelling - new targets for therapy in cardiovascular disease.

Authors:  D Pons; J W Jukema
Journal:  Neth Heart J       Date:  2008       Impact factor: 2.380

3.  Self-assembled hydrophobic honokiol loaded MPEG-PCL diblock copolymer micelles.

Authors:  MaLing Gou; XiuLing Zheng; Ke Men; Juan Zhang; BiLan Wang; Lei Lv; XiuHong Wang; YinLan Zhao; Feng Luo; LiJuan Chen; Xia Zhao; YuQuan Wei; ZhiYong Qian
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

4.  Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells in vitro and in vivo.

Authors:  Qian-mei Zhou; Xiu-feng Wang; Xin-jun Liu; Hui Zhang; Yi-yu Lu; Shi-bing Su
Journal:  Acta Pharmacol Sin       Date:  2011-10-10       Impact factor: 6.150

Review 5.  Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents.

Authors:  Mélanie Poivre; Pierre Duez
Journal:  J Zhejiang Univ Sci B       Date:  2017 Mar.       Impact factor: 3.066

6.  Berberine cooperates with adrenal androgen dehydroepiandrosterone sulfate to attenuate PDGF-induced proliferation of vascular smooth muscle cell A7r5 through Skp2 signaling pathway.

Authors:  Jia Liu; Jian Xiu; Junxian Cao; Qianping Gao; Dan Ma; Lu Fu
Journal:  Mol Cell Biochem       Date:  2011-05-01       Impact factor: 3.396

Review 7.  The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer.

Authors:  Michael Y Bonner; Jack L Arbiser
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

8.  c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation.

Authors:  Tamara Lotan; Jonathan Hickson; Jeffrey Souris; Dezheng Huo; Jennifer Taylor; Terry Li; Kristen Otto; Seiko Diane Yamada; Kay Macleod; Carrie W Rinker-Schaeffer
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

9.  Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells.

Authors:  Natalia N Mendelev; Verietta S Williams; David A Tulis
Journal:  J Cardiovasc Pharmacol       Date:  2009-02       Impact factor: 3.105

10.  Honokiol inhibits tumor necrosis factor-α-stimulated rat aortic smooth muscle cell proliferation via caspase- and mitochondrial-dependent apoptosis.

Authors:  Shuli Fan; Xu Li; Jie Lin; Sijiao Chen; Jinhua Shan; Guoxian Qi
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.